Kaupmann K, Malitschek B, Schuler V, Heid J, Froestl W, Beck P, Mosbacher J, Bischoff S, Kulik A, Shigemoto R, Karschin A, Bettler B
Novartis Pharma AG, TA Nervous System, Basel, Switzerland.
Nature. 1998 Dec 17;396(6712):683-7. doi: 10.1038/25360.
B-type receptors for the neurotransmitter GABA (gamma-aminobutyric acid) inhibit neuronal activity through G-protein-coupled second-messenger systems, which regulate the release of neurotransmitters and the activity of ion channels and adenylyl cyclase. Physiological and biochemical studies show that there are differences in drug efficiencies at different GABA(B) receptors, so it is expected that GABA(B)-receptor (GABA(B)R) subtypes exist. Two GABA(B)-receptor splice variants have been cloned (GABA(B)R1a and GABA(B)R1b), but native GABA(B) receptors and recombinant receptors showed unexplained differences in agonist-binding potencies. Moreover, the activation of presumed effector ion channels in heterologous cells expressing the recombinant receptors proved difficult. Here we describe a new GABA(B) receptor subtype, GABA(B)R2, which does not bind available GABA(B) antagonists with measurable potency. GABA(B)R1a, GABA(B)R1b and GABA(B)R2 alone do not activate Kir3-type potassium channels efficiently, but co-expression of these receptors yields a robust coupling to activation of Kir3 channels. We provide evidence for the assembly of heteromeric GABA(B) receptors in vivo and show that GABA(B)R2 and GABA(B)R1a/b proteins immunoprecipitate and localize together at dendritic spines. The heteromeric receptor complexes exhibit a significant increase in agonist- and partial-agonist-binding potencies as compared with individual receptors and probably represent the predominant native GABA(B) receptor. Heteromeric assembly among G-protein-coupled receptors has not, to our knowledge, been described before.
神经递质γ-氨基丁酸(GABA)的B型受体通过G蛋白偶联的第二信使系统抑制神经元活动,该系统调节神经递质的释放以及离子通道和腺苷酸环化酶的活性。生理学和生化研究表明,不同的GABA(B)受体在药物效率上存在差异,因此预计存在GABA(B)受体(GABA(B)R)亚型。已经克隆出两种GABA(B)受体剪接变体(GABA(B)R1a和GABA(B)R1b),但天然GABA(B)受体和重组受体在激动剂结合效力上表现出无法解释的差异。此外,在表达重组受体的异源细胞中激活假定的效应离子通道被证明很困难。在此,我们描述了一种新的GABA(B)受体亚型GABA(B)R2,它不能以可测量的效力结合现有的GABA(B)拮抗剂。单独的GABA(B)R1a、GABA(B)R1b和GABA(B)R2不能有效地激活Kir3型钾通道,但这些受体的共表达会产生与Kir3通道激活的强大偶联。我们提供了体内异聚GABA(B)受体组装的证据,并表明GABA(B)R2和GABA(B)R1a/b蛋白可免疫沉淀并共同定位于树突棘。与单个受体相比,异聚受体复合物在激动剂和部分激动剂结合效力上有显著增加,可能代表了主要的天然GABA(B)受体。据我们所知,G蛋白偶联受体之间的异聚组装此前尚未被描述过。